Haitham Amal - Amal Lab
@haitham_amal
Followers
884
Following
1K
Media
120
Statuses
544
Satell Family Endowed Chair, Associate Prof. HUJI & @harvard Krill Prize @Wolfprize_, @MIT_alumni, Affiliate @Broadinstitute Founder & CSO NeuroNOS & Point6Bio.
Boston, MA
Joined October 2017
I'm super excited and proud to share our paper in Advanced Science. We proved that #nitricoxide (NO) is a major pathological factor in #autism by looking into the molecular, cellular & behavioral levels. Huge thanks to my amazing team led by @themanish77
advanced.onlinelibrary.wiley.com
This novel work reveals for the first time that nitric oxide (NO) plays a significant role in autism spectrum disorder (ASD) development. The findings will open future directions in order to examine...
28
14
67
Harvard community, please join my talk next Monday at the Pathology Division, @BostonChildrens and @harvardmed.
2
1
7
The #FDA grants my pharmaceutical company Orphan Drug Designation for #Glioblastoma I am pleased to announce that the FDA has granted my company NeuroNOS Orphan Drug Designation for brain tumors, which will facilitate the development of the drug for final approval. Pictured:
2
0
4
Hot off the press! Our new paper in @BrainStimJ shows how 10 Hz r(T)MS induces synaptic plasticity via coordinated pre- & postsynaptic activation and BDNF/TrkB signaling. STDP modeling predicts frequency dependence. Kudos to @GalanisChr & the team!
brainstimjrnl.com
Transcranial magnetic stimulation (TMS) is a widely used non-invasive technique, yet its cellular and molecular mechanisms remain incompletely understood. Current protocols are largely heuristic,...
2
7
25
I'll be speaking at Synchrony 2025 on Aug 22 - 24, 2025. I would love to see you there! - via #Whova Event Platform https://t.co/mYZBdGEQMP
@Neuro_NOS @BostonChildrens @HebrewU
0
0
2
#ThrowbackThursday: Prof. @haitham_amal’s lab (our CSO) found disrupted autophagy proteins in two ASD models, driven by NO imbalance. Blocking nNOS restored normal function—reinforcing NeuroNOS’s approach to rebalance NO & tackle core ASD biology. #AutismResearch #NeuroNOS
0
2
2
Dr. Igor Khaliulin, our lab manager in the past 6 years, is leaving back to his family in the UK. Igor, your contribution to the #AmalLab was very valuable. We will miss you
1
0
4
📽️Sneak peak: We spoke with three world-class scientists, joined by our two extraordinary Nobel Laureates who serve on our Scientific Advisory Board (SAB), as well as our CSO, to discuss our novel small-molecule nitric oxide inhibition platform for autism. #NobelPrize #Autism
0
3
3
Proud to share that our CSO, Prof. @haitham_amal Amal, joins the #Synchrony2025 Roundtable on neuroenergetics in autism. Excess NO → oxidative stress → mitochondrial strain. Our nNOS-targeted small molecule aims to restore balance. #NO #Autism
https://t.co/HTQBOnZhFq
linkedin.com
What if #autism isn't just behavior but also about how the brain powers itself? New emerging science is revealing that disruptions in brain energy metabolism, involving mitochondrial dysfunction,...
0
2
2
🎧 Prof. @haitham_amal, CSO @NeuroNOS, explains how NO dysregulation drives Phelan‑McDermid Syndrome (PMS) & how our FDA‑orphan small molecule advances to first‑in‑human trials in 2026. Watch ▶️ https://t.co/9JT8589bzl
#PMSF #CureSHANK #RareDisease #Autism #DrugDiscovery
0
2
3
My friends in Connecticut, Join the seminar at the Department of Physiology and Neurobiology in University of Connecticut on Thursday. @uconnhealth @UConn @TheUConnBlog
0
1
6
What an incredible session and discussion today at #INSAR2025 Thanks to the wonderful scientific and autism community!
0
1
12
Excited to announce our session at #INSAR2025 in Seattle! I’ll be chairing and speaking about the latest advancements in developing a drug for #autism. We have an incredible lineup of speakers: Stuart Lipton, Michelle Jacob, Lidia Gabis, and Haitham Amal.
1
0
6
🧠 Just out in @brainstimj: Our review explores how rTMS modulates microglia, influencing neuroinflammation, plasticity, and brain repair. Ready to explore the immune dimension of neuromodulation ?! #Freiburg #Neuroanatomy 👉
brainstimjrnl.com
Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation technique used to modulate neocortical excitability, with expanding applications in neurological and psychiat...
0
6
21
Very proud of this achievement by our Company, @Neuro_NOS ! Got an approval from the FDA! @CureSHANK @McdermidPhelan @PhelanMcDermid
@AmFriendsHU @HebrewU
https://t.co/AkJTHIGAwC
https://t.co/aGbVfxGpTy
https://t.co/vOLP20OG86
neuro-nos.com
Home | Neuronos
@Neuro_NOS is excited to share the BIG news from the #FDA! The #FDA granted us an Orphan Drug Designation for #PhelanMcDermidSyndrome, a Neurodevelopmental Disorder Linked to #Autism #OrphanDrug #NitricOxide #PMS #RareDisease
https://t.co/uVzF31IKBH
2
2
8
Big news from @Neuro_NOS @NobelPrize Dan Shechtman joined our Scientific Advisory Board, becoming the second Nobel Prize winner on the team alongside Prof. Roger Kornberg. His groundbreaking insights will help advance our therapy development for #autism and #Alzheimer
1
4
7
Happy to share a new paper of the #AmalLab on the role of autophagy in #autism led my students Eden Deri and Shashank Ojha. @HebrewU @BostonChildrens @AmFriendsHU
https://t.co/0rUHx5moFc
nature.com
Scientific Reports - Multi-omics study reveals differential expression and phosphorylation of autophagy-related proteins in autism spectrum disorder
0
1
9
Highly cited manuscripts @NIOX_Journal @elsbiomedchem Effects of extended-release 7-nitroindazole gel formulation treatment on the behavior of Shank3 mouse model of autism By Muhammad Abdel-Haq, Haitham Amal @haitham_amal et al. https://t.co/PCBunF0g11
0
1
0
Another milestone in #Alzheimer’s disease by the #AmalLab discovering early shared molecular mechanisms between different mutations of the disease! Thanks to the Ashery Lab for the contribution. @HebrewU @TelAvivUni @BostonChildrens
https://t.co/Lja2KTh2wX
nature.com
Translational Psychiatry - Shared early molecular mechanisms revealed in P301S and 5xFAD Alzheimer’s disease mouse models
0
2
10
חברת NeuroNOS גייסה הון ראשוני של 2 מיליון דולר ממשקיעים פרטיים. הגיוס יאיץ את הפיתוח הפרה-קליני של התרופה של NeuroNOS המיועדת לילדים עם אוטיזם. התרופה מנצלת את ויסות רמות תחמוצת החנקן (NO) במוח כדי להשפיע באופן משמעותי על התפקוד הנוירולוגי. https://t.co/yxS8e51jKa
0
2
6
I’m very proud of the technology that was developed at the #AmalLab! As the Co-Founder and CSO of the company, I’m very excited to announce that #NeuroNOS has secured 2M$ of funding to advance development of an innovative #autism therapy. @HebrewU_heb @AmFriendsHU @yissumhuji
Securing 2M$! Exciting news! A new era of developing a drug for #Autism! We are excited to announce our recent milestone. NeuroNOS Secures $2.0 Million in Funding to Advance Development of an Innovative #Autism #Therapy. The funds will drive development forward, with clinical
2
2
23